When is OncoTherapy Science reporting earnings?

OncoTherapy Science has an earnings announcement scheduled for 30 Jan 2026. Expect management comments on trial progress, R&D spend, and cash runway that could drive intraday moves in 4564.T stock.

What are the biggest drivers for 4564.T stock price?

Clinical readouts, especially Phase III S-588410 news, and capital raises. Also watch revenue trends, cash-per-share, and any guidance tied to R&D and milestone income.

What is Meyka AI’s short-term forecast for 4564.T stock?

Meyka AI's monthly model gives **JPY 28.51**, a **+35.76%** upside. The yearly projection is **JPY 18.22**, a **-13.24%** downside. These are model-based projections and not guarantees.

How risky is investing in 4564.T stock?

Biotech risk is high due to binary trial outcomes and dilution risk. OncoTherapy shows strong liquidity but negative EPS. Investors should weigh clinical risk versus balance-sheet strength.

JP Stocks

4564.T OncoTherapy Science JPX 29 Jan 2026 earnings ahead: clinical readout may move stock

ByHuzaifa Zahoor January 29, 2026

We see 4564.T stock trading at JPY 21.00 intraday on the JPX as OncoTherapy Science prepares an earnings update around its clinical program. Volume today is 28,911,900.00 shares while the 50-day average is 21.24 JPY. The earnings release on 30 Jan 2026 will spotlight Phase III S-588410 progress and near-term funding needs. Investors should watch clinical milestones and cash-per-share metrics that could drive short-term moves.